Doxylamine


Description

Histamine H1 antagonist with pronounced sedative properties. It is used in allergies and as an antitussive, antiemetic, and hypnotic. Doxylamine has also been administered in veterinary applications and was formerly used in parkinsonism.

Read more

Pharmacology

Indication

Used alone as a short-term sleep aid, in combination with other drugs as a night-time cold and aller... Read more

Pharmacodynamic

Doxylamine is an antihistamine commonly used as a sleep aid. This drug is also used to relieve sympt... Read more

Mechanism of action

Like other antihistamines, doxylamine acts by competitively inhibiting histamine at H1 receptor... Read more

Absorption

Readily absorbed via the gastrointestinal tract.

Protein binding

Information currently not available.

Volume of distribution

Information currently not available.

Clearance

Information currently not available.

Half life

10 hours

Route of elimination

Information currently not available.

Toxicity

Signs of overdose include wheezing, tightness in the chest, fever, itching, bad cough, blue skin col... Read more


Adverse Effects

Effect Regions Age Groups Incidences Evidence Type

Contraindications

Information currently not available.

Food Interactions

    Information currently not available.

Interactions

Type in a drug name to check for interaction with Doxylamine

The therapeutic efficacy of Doxylamine can be decreased when used in combination with 1,10-Phenanthroline.
2,5-Dimethoxy-4-ethylamphetamine may decrease the sedative and stimulatory activities of Doxylamine.
Doxylamine may increase the central nervous system depressant (CNS depressant) activities of 2,5-Dimethoxy-4-ethylthioamphetamine.
Doxylamine may increase the central nervous system depressant (CNS depressant) activities of 4-Bromo-2,5-dimethoxyamphetamine.
Doxylamine may increase the central nervous system depressant (CNS depressant) activities of 4-Methoxyamphetamine.
Doxylamine may increase the central nervous system depressant (CNS depressant) activities of 5-methoxy-N,N-dimethyltryptamine.
Doxylamine may increase the central nervous system depressant (CNS depressant) activities of 7-Nitroindazole.
Doxylamine may increase the central nervous system depressant (CNS depressant) activities of 7,8-Dichloro-1,2,3,4-tetrahydroisoquinoline.
The risk or severity of Tachycardia can be increased when Doxylamine is combined with Abediterol.
The risk or severity of QTc prolongation can be increased when Doxylamine is combined with Abexinostat.
The risk or severity of QTc prolongation can be increased when Doxylamine is combined with Acebutolol.
Doxylamine may increase the central nervous system depressant (CNS depressant) activities of Acepromazine.
Doxylamine may increase the central nervous system depressant (CNS depressant) activities of Aceprometazine.
Doxylamine may increase the central nervous system depressant (CNS depressant) activities of Acetazolamide.
Doxylamine may increase the central nervous system depressant (CNS depressant) activities of Acetophenazine.
The risk or severity of QTc prolongation can be increased when Doxylamine is combined with Acetyldigoxin.
Doxylamine may increase the central nervous system depressant (CNS depressant) activities of Acetylglycinamide chloral hydrate.
The risk or severity of adverse effects can be increased when Doxylamine is combined with Aclidinium.
The therapeutic efficacy of Doxylamine can be decreased when used in combination with Acotiamide.
The risk or severity of QTc prolongation can be increased when Doxylamine is combined with Acrivastine.

References

    Information currently not available.

Recent Questions